The Future of
Drug Discovery is Here.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Who We Are
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
What We Do
Duis irure dolor reprehenderit
in voluptate velit esse cillum
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Client Outcomes
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
News
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Notice Regarding Unauthorized Access to an Employee Email Account
Fujisawa, Japan – July 22, 2026 – We have confirmed that a third party gained unauthorized access...
A paper describing the drug discovery research of the CDK12 inhibitor CTX-439 has been published in ACS Medicinal Chemistry Letters
Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug Publication Published Date:...
Axcelead DDP Joins Lilly TuneLab to Advance AI Drug Discovery
Fujisawa, Japan, June 18, 2026 — Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) is pleased to announce...